Once‐weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double‐blind, placebo‐controlled trial
…, JM Kremer, S Kafka, M Lovy, T DeVries… - … : Official Journal of …, 2004 - Wiley Online Library
Objective To evaluate the safety, efficacy, and pharmacokinetics of 50 mg etanercept
administered subcutaneously once weekly in adult patients with active rheumatoid arthritis (RA). …
administered subcutaneously once weekly in adult patients with active rheumatoid arthritis (RA). …
[PDF][PDF] Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma
…, EL Sievers, SD Hughes, TA DeVries… - Journal of clinical …, 2008 - researchgate.net
Purpose A phase I study of patients with metastatic malignant melanoma (MM) and renal
cell carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD), …
cell carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD), …
[HTML][HTML] Combining immunotherapy and radiation for prostate cancer
…, AM Agassi, Y Rotterman, T DeVries… - Clinical genitourinary …, 2015 - Elsevier
… Todd DeVries is an employee and shareholder at Dendreon. Robert Sims was an employee
(during the drafting of this report) and is a shareholder at Dendreon. The remaining authors …
(during the drafting of this report) and is a shareholder at Dendreon. The remaining authors …
Humoral immune response against nontargeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome
…, EJ Small, TA Gardner, K Bailey, T Vu, T DeVries… - Clinical Cancer …, 2015 - AACR
Purpose: Antitumor activity of cancer immunotherapies may elicit immune responses to
nontargeted (secondary) tumor antigens, or antigen spread. We evaluated humoral antigen …
nontargeted (secondary) tumor antigens, or antigen spread. We evaluated humoral antigen …
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma …
…, W Bensinger, M Cota, T Doerr, T DeVries… - 2020 - ascopubs.org
8504 Background: Orva-cel is an investigational, BCMA-directed CAR T cell product with a
fully human binder. Over 100 pts have been treated in the EVOLVE phase 1 study. Pts treated …
fully human binder. Over 100 pts have been treated in the EVOLVE phase 1 study. Pts treated …
[HTML][HTML] JCARH125, anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: initial proof of concept results from a phase 1/2 multicenter study …
S Mailankody, M Htut, KP Lee, W Bensinger, T Devries… - Blood, 2018 - Elsevier
Introduction: B-cell maturation antigen (BCMA) is expressed on malignant plasma cells and
is an attractive therapeutic target for multiple myeloma. BCMA CAR T-cells, antibody drug …
is an attractive therapeutic target for multiple myeloma. BCMA CAR T-cells, antibody drug …
A randomized phase II trial of sipuleucel-T with concurrent versus sequential abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer
Purpose: This phase II open-label study evaluated the effect of concurrent or sequential
administration of abiraterone acetate plus prednisone (AA + P) on sipuleucel-T manufacture and …
administration of abiraterone acetate plus prednisone (AA + P) on sipuleucel-T manufacture and …
Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
OBJECTIVE: To examine the baseline demographic and disease characteristics that might
influence improvement as measured by the Assessment in Ankylosing Spondylitis Response …
influence improvement as measured by the Assessment in Ankylosing Spondylitis Response …
Clonotypic diversification of intratumoral T cells following sipuleucel-T treatment in prostate cancer subjects
Sipuleucel-T is an autologous cellular therapy for asymptomatic, or minimally symptomatic,
metastatic castrate-resistant prostate cancer, designed to stimulate an immune response …
metastatic castrate-resistant prostate cancer, designed to stimulate an immune response …
Sequencing of sipuleucel-T and androgen deprivation therapy in men with hormone-sensitive biochemically recurrent prostate cancer: a phase II randomized trial
…, FE Millard, JC Maher, NN Chang, T DeVries… - Clinical Cancer …, 2017 - AACR
Purpose: STAND, a randomized, phase II, open-label trial (NCT01431391), assessed
sequencing of sipuleucel-T (an autologous cellular immunotherapy) with androgen deprivation …
sequencing of sipuleucel-T (an autologous cellular immunotherapy) with androgen deprivation …